Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2019 year
    10 month
    31 day
    A strategic cooperation agreement was signed with Daiichi-Sankyo

    Hong Kong Winhealth Pharma Group (hereinafter referred to as Winhealth Pharma) declared to have come to a strategic cooperation agreement on Asmeton® product with Daiichi-Sankyo Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as Daiichi-Sankyo) on October 31, 2019.


    Daiichi-Sankyo will grant the right of promotion of Asmeton® in non-core regions in Chinese Mainland to Winhealth Pharma, and the latter will be responsible for commercial operation in non-core regions in Chinese Mainland, involving sales, channel management and product lifecycle management.


    A strategic cooperation agreement was signed with Daiichi-Sankyo A strategic cooperation agreement was signed with Daiichi-Sankyo


    Asmeton® (Compound Methoxyphenamine Capsules) produced by Daiichi-Sankyo is used for treating bronchial asthma and asthmatic bronchitis, as well as such symptoms as cough, expectoration and gasp caused by other respiratory diseases. It’s a preferred cough medicine recommended in guidelines, and is extensively used in domestic patient populations. It has good efficacy for acute bronchitis cough, cough variant asthma and the like.


    Asmeton capsules contain methoxyphenamine hydrochloride, which can inhibit bronchospasm and relieve the cough during asthmatic attack. Narcotine is a peripheral cough medicine and can inhibit cough. Aminophylline also can inhibit bronchospasm, bronchial mucosal swelling, relieve the cough during asthmatic attack and make it easy to cough up the phlegm. Chlorpheniramine maleate has an antihistamine function and can inhibit the cough caused by upper respiratory inflammation. This product can alleviate the cough caused by inflammation in the throat and bronchus, relieve the cough during asthmatic attack and facilitate sputum excretion.


    A strategic cooperation agreement was signed with Daiichi-Sankyo A strategic cooperation agreement was signed with Daiichi-Sankyo


    Due to the initial cooperation of both parties, Winhealth Pharma will make full use of its diversified nationwide sales network and academic-based customized market strategy to continuously cover the life cycles of products, help the clinical treatment of Chinese patients and further promote the development of the health undertaking of China.

     

    About Hong Kong Winhealth Pharma Group

    Founded in Hangzhou in 2006 and headquartered in Hong Kong, China, Winhealth Pharma Group is a one-stop professional service platform focusing on the whole process from drug registration submission, product import, market access, commercialization and life cycle management.

    As a new pharmaceutical enterprise promoting the development of China pharmaceuticals and health industry, Winhealth Pharma Group is dedicated to introducing world-leading health products and medical technologies into the China market, providing more excellent therapies and medical information dissemination channels for medical workers and more treatment and rehabilitation resources for patients, and creating a leading full-cycle, integrated and customized market access solution supplier and CDCO (contract development and commercialization organization, a commercialization service platform).

    Please visit the official website of Hong Kong Winhealth Pharma Group for more information: http://www.winhealth.hk/


    About Daiichi-Sankyo Pharmaceutical (Shanghai) Co., Ltd.

    Daiichi-Sankyo Pharma (Shanghai) Co., Ltd. is a wholly-owned subsidiary of Daiichi-Sankyo Co., Ltd., a world famous reference listed drug manufacturing group. It’s mainly engaged in the development, production, sales and consultation, as well as import, export and wholesales of pharmaceuticals. As the core of the undertaking of Daiichi-Sankyo in China, the company has been making unremitting efforts for the whole group to realize the corporation vision (global drug innovator), constantly introducing world-leading products and technologies, conducting production and quality control strictly in accordance with the GMP, delivering the latest clinical drug information and therapies to medical workers timely and accurately with professional service awareness and dedication spirit, and making contribution to improving the quality of life of patients.

    3rd Floor, Weijian Health Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.